ClinicalTrials.gg
CompletedNCT01873417MANAGEUpdated Mar 21, 2017Results posted

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

A Phase 4 interventional study of BG00012 (DMF) in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
237
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.

Enrollment
6th of 22
237 · median 86
Started
2013
with 2 others
Phase 4
10 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
17 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 6th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 4, and was the 7th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal (GI)-related events reported by participants with relapsing forms of multiple sclerosis (MS) initiating therapy with dimethyl fumarate (DMF) in the clinical practice setting.

The secondary objectives of this study are as follows:

  • To evaluate GI-related events requiring symptomatic therapy and the role of those therapies over time in participants with relapsing forms of MS initiating therapy with DMF in the clinical practice setting.
  • To evaluate GI-related events that lead to DMF discontinuation after the use of symptomatic therapy in participants with relapsing forms of MS initiating therapy with DMF in the clinical practice setting.
03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Decision to treat with DMF must precede enrollment.
  • Naïve to DMF or fumaric acid esters.
  • Resides in the US and has a confirmed diagnosis of a relapsing form of MS.
  • Satisfies the approved therapeutic indication(s) for DMF.

Key Exclusion Criteria:

  • Inability to comply with study requirements or, at the discretion of the Investigator, is deemed unsuitable for study participation.
  • History of significant GI disease, chronic use of GI symptomatic therapy, active .
  • Is participating in any other interventional clinical trial.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    Dimethyl Fumarate

    120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).

    Drug: BG00012 (DMF)

Interventions

  • Also known as: Tecfidera, DMF, dimethyl fumarate

06

What researchers measure

Primary outcomes

  1. Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)

    Severity of GI-related events in DMF-treated participants using the MOGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

    Time frame: 12 Weeks

  2. Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale

    Severity of GI-related events in DMF-treated participants using the MAGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

    Time frame: 12 Weeks

  3. Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy

    Percentage of participants reporting GI symptoms on the MOGISS, by those who utilized symptomatic therapy.

    Time frame: 12 Weeks

  4. Duration of GI-related Episodes in DMF-treated Participants

    In participants who took symptomatic therapy, the median duration of acute GI episodes (in hours) was summarized for the overall treatment period, by symptom (nausea, diarrhea, lower abdominal pain, upper abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence). Table only includes the symptom duration for those symptoms with start and stop times entered in the eDiary (evaluable GI episodes), based on the MAGISS.

    Time frame: 12 Weeks

Secondary outcomes

  1. Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy

    Percentage of participants reporting that they required GI symptomatic therapy, based on the MOGISS.

    Time frame: 12 Weeks

  2. Participants' Use of Symptomatic Therapy, by Type and Category

    The symptomatic therapies used by DMF-treated participants were self-reported by type and category. Each participant may have taken more than one symptomatic therapy type but was counted only once within each therapy category. Acetylsalicylic acid (ASA) is abbreviated in the table.

    Time frame: 12 Weeks

  3. Summary of Use and Days on Symptomatic Therapy, by Category

    The total duration (in days) of use of each symptomatic therapy by participants as a result of GI symptoms experienced by DMF-treated participants is presented. If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in the 'All Therapies' category.

    Time frame: 12 Weeks

  4. Number of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy

    The last symptomatic therapy prior to last dose of study medication was used to summarize the number of participants who discontinued DMF due to GI-related events. Participants may have taken more than one symptomatic therapy but are counted only once in the 'All Therapies' category.

    Time frame: 12 Weeks

07

Results

Posted Nov 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneDimethyl Fumarate
Started237
Safety population233
Completed202
Not completed35
Withdrew: Did not receive any study drug4
Withdrew: Adverse event24
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject2
Withdrew: Physician decision3

Outcome measures

PrimaryWorst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)

Severity of GI-related events in DMF-treated participants using the MOGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

Time frame:
12 Weeks
Reported as:
Mean · units on a scale
Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)
units on a scaleDimethyl Fumarate
Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)4.8 ± 2.34
PrimaryWorst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale

Severity of GI-related events in DMF-treated participants using the MAGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.

Time frame:
12 Weeks
Reported as:
Mean · units on a scale
Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale
units on a scaleDimethyl Fumarate
Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale4.7 ± 2.13
PrimaryPercentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy

Percentage of participants reporting GI symptoms on the MOGISS, by those who utilized symptomatic therapy.

Time frame:
12 Weeks
Reported as:
Number · percentage of participants
Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy
percentage of participantsDimethyl Fumarate
Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy54.1
PrimaryDuration of GI-related Episodes in DMF-treated Participants

In participants who took symptomatic therapy, the median duration of acute GI episodes (in hours) was summarized for the overall treatment period, by symptom (nausea, diarrhea, lower abdominal pain, upper abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence). Table only includes the symptom duration for those symptoms with start and stop times entered in the eDiary (evaluable GI episodes), based on the MAGISS.

Time frame:
12 Weeks
Reported as:
Median · hours
Duration of GI-related Episodes in DMF-treated Participants
hoursDimethyl Fumarate
Nausea; n=882.0 ± 1.81
Diarrhea; n=781.6 (0.0 to 11.0)
Lower Abdominal Pain; n=672.0 (0.0 to 8.0)
Upper Abdominal Pain; n=661.8 (0.1 to 9.5)
Vomiting; n=270.4 (0.0 to 8.0)
Indigestion; n=521.9 (0.0 to 11.0)
Constipation; n=76.0 (0.0 to 23.0)
Bloating; n=413.0 (0.0 to 12.7)
Flatulence; n=682.1 (0.2 to 12.7)
SecondaryPercentage of DMF-treated Participants Who Required GI Symptomatic Therapy

Percentage of participants reporting that they required GI symptomatic therapy, based on the MOGISS.

Time frame:
12 Weeks
Reported as:
Number · percentage of participants
Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy
percentage of participantsDimethyl Fumarate
Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy54.1
SecondaryParticipants' Use of Symptomatic Therapy, by Type and Category

The symptomatic therapies used by DMF-treated participants were self-reported by type and category. Each participant may have taken more than one symptomatic therapy type but was counted only once within each therapy category. Acetylsalicylic acid (ASA) is abbreviated in the table.

Time frame:
12 Weeks
Reported as:
Number · participants
Participants' Use of Symptomatic Therapy, by Type and Category
participantsDimethyl Fumarate
Category: Antacid57
Therapy: Calcium carbonate50
Therapy: Magnesium (Mg) hydroxide4
Therapy: Aluminum (Al) hydroxide1
Therapy: Al hydroxide, Mg hydroxide, simethicone3
Therapy: ASA, citric acid, sodium bicarbonate2
Therapy: Generic anatacid1
Therapy: Nauzene1
Therapy: Sucralfate1
Category: Antisecretory/antimicrobial49
Therapy: Bismuth subsalicylate49
Category: Anti-acid production43
Therapy: Omeprazole18
Therapy: Ranitidine15
Therapy: Famotidine14
Therapy: Lansoprazole10
Therapy: Pantoprazole3
Therapy: Cimetidine1
Category: Anti-bloating/anti-constipation agent33
Therapy: Simethicone29
Therapy: Docusate5
Therapy: Alpha-galactosidase1
Therapy: Enema1
Category: Antidiarrheal (anti-peristaltic)32
Therapy: Loperamide29
Therapy: Diphenoxylate3
Therapy: Dicyclomine2
Category: Anti-emetic (central)18
Therapy: Ondansetron8
Therapy: Promethazine7
Therapy: Dimenhydrinate3
Therapy: Tetrahydrocannabinol1
Category: Laxative, fiber/probiotic10
Therapy: Generic laxative5
Therapy: Psyllium fiber3
Therapy: Culturelle2
Category: Laxative, hygroscopic/osmotic10
Therapy: Polyethylene glycol4
Therapy: Phosphorated carbohydrate solution3
Therapy: Sennosides2
Therapy: Osmotic1
Category: Laxative, prokinetic7
Therapy: Bisacodyl7
Category:Analgesic (nonsteroidal antiinflammatory)5
Therapy: Ibuprofen3
Therapy: Naproxen2
Therapy: ASA1
Category: Anti-allergic3
Therapy: Montelukast2
Therapy: Diphenhydramine1
Category: Anti-emetic (pro-kinetic)3
Therapy: Metoclopramide3
Category: Analgesic2
Therapy: Acetaminophen2
Category: No treatment type recorded1
Therapy: Not available1
SecondarySummary of Use and Days on Symptomatic Therapy, by Category

The total duration (in days) of use of each symptomatic therapy by participants as a result of GI symptoms experienced by DMF-treated participants is presented. If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in the 'All Therapies' category.

Time frame:
12 Weeks
Reported as:
Mean · days
Summary of Use and Days on Symptomatic Therapy, by Category
daysDimethyl Fumarate
All therapies; n=12810.4 ± 13.46
Antacid; n=575.9 ± 10.77
Antisecretory/antimicrobial; n=496.3 ± 12.34
Anti-acid production; n=439.0 ± 11.16
Anti-bloating/anti-constipation agent; n=335.9 ± 10.86
Anti-diarrheal (anti-peristaltic); n=323.9 ± 3.88
Anti-emetic (central); n=182.9 ± 2.00
Laxative, fiber/probiotic; n=105.0 ± 5.64
Laxative, hygroscopic/osmotic; n=103.7 ± 3.06
Laxative, prokinetic; n=71.6 ± 0.79
Analgesic (nonsteroidal antiinflammatory); n=54.6 ± 7.50
Anti-allergic; n=312.0 ± 9.85
Anti-emetic; n=39.7 ± 12.42
Analgesic; n=24.5 ± 4.95
No treatment type recorded; n=11.0 ± NA
SecondaryNumber of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy

The last symptomatic therapy prior to last dose of study medication was used to summarize the number of participants who discontinued DMF due to GI-related events. Participants may have taken more than one symptomatic therapy but are counted only once in the 'All Therapies' category.

Time frame:
12 Weeks
Reported as:
Number · participants
Number of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy
participantsDimethyl Fumarate
All therapies13
Anti-acid production10
Antacid6
Antisecretory/antimicrobial6
Anti-diarrheal (anti-peristaltic)5
Anti-emetic (central)5
Anti-emetic (prokinetic)2
Laxative, fiber/probiotic1
Laxative, prokinetic1

Adverse events

Collected over All serious adverse events (SAEs) from time of signed/dated informed consent through 12 weeks of treatment plus 4 weeks (± 5 days) post last dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dimethyl Fumarate—7/233 (3%)0/233 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDimethyl Fumarate
DiarrhoeaGastrointestinal disorders2/233
Abdominal Pain LowerGastrointestinal disorders1/233
Abdominal Pain UpperGastrointestinal disorders1/233
NauseaGastrointestinal disorders1/233
Salivary Gland CalculusGastrointestinal disorders1/233
VomitingGastrointestinal disorders1/233
LymphadenitisBlood and lymphatic system disorders1/233
Atrial FibrillationCardiac disorders1/233
Sudden Cardiac DeathGeneral disorders1/233
Troponin IncreasedInvestigations1/233

Baseline characteristics

Safety Population (participants who received at least 1 dose of DMF, recorded in diary data)

Age, Continuous
Age, Continuous(years)Dimethyl Fumarate
Mean46.9 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Dimethyl Fumarate
Female181
Male52
08

Study locations

37 sites
  • Research Site
    Cullman, Alabama 35058, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Scottsdale, Arizona 85258, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Pasadena, California 91105, United States
  • Research Site
    Englewood, Colorado 80113, United States
  • Research Site
    Fort Collins, Colorado 80528, United States
  • Research Site
    Danbury, Connecticut 06810, United States
  • Research Site
    Maitland, Florida 32751, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    North Palm Beach, Florida 33408, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    St. Petersburg, Florida 33713, United States
  • Research Site
    Tampa, Florida 33609, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30327, United States
  • Research Site
    Indianapolis, Indiana 46256, United States
  • Research Site
    Milford, Massachusetts 01757, United States
  • Research Site
    Golden Valley, Minnesota 55422, United States
  • Research Site
    Patchogue, New York 11772, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Greensboro, North Carolina 27405, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Portland, Oregon 97225, United States
  • Research Site
    Monroeville, Pennsylvania 15215, United States
  • Research Site
    Cordova, Tennessee 38018, United States
  • Research Site
    Franklin, Tennessee 37064, United States
  • Research Site
    Knoxville, Tennessee 37934, United States
  • Research Site
    Round Rock, Texas 78681, United States
  • Research Site
    Salt Lake City, Utah 84103, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Roanoke, Virginia 24018, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Milwaukee, Wisconsin 53215, United States
09

References and documents

Publications

  • Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, Li J, Zambrano J. Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE). Int J MS Care. 2016 Jan-Feb;18(1):9-18. doi: 10.7224/1537-2073.2014-101. PubMed 26917993 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2013
First posted
Jun 10, 2013
Start
May 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Nov 11, 2014
Last update
Mar 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01873417
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jun 10, 2013
Start date
May 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Nov 11, 2014
Last update
Mar 21, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion